Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models

Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models

Abstract So far, only a small number of medications are effective in progressive multiple sclerosis (MS). The sphingosine-1-phosphate-receptor (S1PR)-1,5 modulator siponimod, licensed for progressive MS, is acting both on peripheral immune cells and in the central nervous system (CNS). So far it rem...

Full description

Bibliographic Details
Main Authors: Hasan Hüseyin Hendek, Alina Blusch, Neele Heitmann, Sarah Oberhagemann, Seray Demir, Xiomara Pedreiturria, Ralf Gold, Simon Faissner
Format: Article
Language:English
Published: Nature Portfolio 2024-08-01
Series:Scientific Reports
Subjects:
Multiple sclerosis
Siponimod
Brain derived neurotrophic factor
Experimental autoimmune encephalomyelitis
Neuroprotection
Neuroinflammation
Online Access:https://doi.org/10.1038/s41598-024-68715-x

Internet

https://doi.org/10.1038/s41598-024-68715-x

Similar Items